DENVER, CO- Omni Bio Pharmaceutical, Inc. ("OMNI") (OTCBB: AAFS) announces that it has consummated the previously announced name change from Across America Financial Services, Inc. The Company is in process of having a new ticker symbol assigned to more closely reflect its name and will announce the new symbol once it becomes effective.
Omni also announced the appointment of Robert C. Ogden to the positions of Chief Financial Officer, Secretary and Treasurer of both Omni and its wholly owned subsidiary Omni Bio Operating, Inc. Mr. Ogden will be engaged on a part-time basis and is expected to spend approximately 50% of his time on Company related business.
Mr. Ogden brings 20 years of senior financial management experience in both private and public companies. Since 2007, Mr. Ogden has been a financial consultant providing services ranging from interim Vice President of Finance of an IP telephony software company to SEC reporting and accounting assistance for a multi-national, business process outsourcing services company. From 2004 to 2007, Mr. Ogden served as Chief Financial Officer, Treasurer and Secretary of SAN Holdings, Inc., a publicly traded data storage solutions provider and software company, where he was responsible for all administrative and finance functions. From 2000 to 2004, he was a financial consultant, primarily providing financial controller and financial reporting services for both private and public companies in a variety of industries, including software, computer hardware and financial services. From 1997 to 2000, he served as Vice President, Corporate Controller and Chief Accounting Officer for TAVA Technologies, Inc., a publicly held national systems integration and software company. He began his career as a public accountant with PricewaterhouseCoopers. Mr. Ogden holds a B.S. in Commerce from the University of Virginia and is a CPA.
Additionally, both Omni and Omni Bio Operating, Inc. appointed Edward C. Larkin as Chief Operating Officer and Executive Vice President. Mr. Larkin had served as Omni's interim Chief Financial Officer. He has been associated with Omni and its predecessor, Apro Bio Pharmaceutical, Inc., since January 2007.
No comments:
Post a Comment